IDH3A and intrahepatic cholangiocarcinoma: Results from studies targeting Fibroblast Growth Factor Receptor (FGFR) [8,9,10] and isocitrate dehydrogenase (IDH) [11] (predominantly in intra-hepatic cholangiocarcinoma (ICC)) show promise and are expected to change the treatment paradigm for patients with ICC, although final results of ongoing studies are awaited for confirmation of real benefit (e.g. NCT02428855, NCT02989857, NCT02150967).